Combined antiarrhythmic therapy for refractory paroxysmal atrial fibrillation: a multicenter observational study
Journal of Arrhythmology · 13.06.2026 · 33 (2) · 22-31
DOI: 10.35336/va-1655 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Arrhythmology, online erschienen am 13.06.2026. Verfasst von Yu. G. Shchukina und 12 weiteren Autor:innen. Die Arbeit nennt 17 Literaturangaben.
Abstract (Originalsprache)
Aim
To evaluate the efficacy of the class IC antiarrhythmic drug flecainide in combination with an atrioventricular nodal slowing agent (metoprolol succinate or diltiazem) for the suppression of refractory to other antiarrhythmic medication atrial fibrillation (AF) in patients with symptomatic paroxysmal AF without significant structural heart disease, as well as to assess the incidence of adverse events associated with this therapy. Material and Methods . This multicenter observational study enrolled patients aged 18-75 years with documented symptomatic (EHRA class ≥2a) paroxysmal AF and frequent episodes (≥2 per month). All patients received flecainide combined with either metoprolol succinate or diltiazem. The primary endpoint was a documented episode of AF within 3 months of therapy. Secondary endpoints included time to AF recurrence and treatment-related adverse events. Rhythm monitoring was performed using a portable device for self-recording of lead I electrocardiograms: daily during the first week, twice weekly during weeks 2-4, and additionally on an ad hoc basis when symptoms occurred. Quality of life was assessed using the EQ-5D questionnaire at baseline and at study completion.
Results
The study included 59 patients (57.6% female; mean age 63.5±9.9 years). The combination of flecainide with metoprolol succinate was prescribed to 93.2% (n=55) of patients, and flecainide with diltiazem to 6.8% (n=4). The primary endpoint was reached in 33.9% of patients (n=20). The majority of AF recurrences (85% of all events, n=17) occurred during the first month of follow-up. Adverse events were reported in 10.2% of cases (n=7).
Conclusion
In patients with paroxysmal AF refractory to other antiarrhythmic drugs (including prior ineffective catheter ablation in half of the study patients), a combination of flecainide with metoprolol or diltiazem demonstrated a recurrence-free rate of 66% over 3 months, with an acceptable safety profile. Combination therapy is associated with a significant improvement in quality of life. Single-lead remote ECG monitoring is useful for detecting arrhythmia recurrences but is insufficient for a comprehensive assessment of the safety of intraventricular conduction disturbances.
Zitieren
APA
Shchukina, Y. G., Gasimova, N. Z., Kobzar, L. Y., Gordeeva, M. S., Harlap, M. S., Serdyuk, S. E., Tarasov, A. V., Davtyan, K. V., Livadny, E. S., Mamchur, S. E., Lebedev, D. S., Mikhaylov, E. N., & Leandro, H. I. C. (2026). Combined antiarrhythmic therapy for refractory paroxysmal atrial fibrillation: a multicenter observational study. Journal of Arrhythmology, 33(2), 22-31. https://doi.org/10.35336/va-1655
Vancouver
Shchukina YG, Gasimova NZ, Kobzar LY, Gordeeva MS, Harlap MS, Serdyuk SE, et al. Combined antiarrhythmic therapy for refractory paroxysmal atrial fibrillation: a multicenter observational study. Journal of Arrhythmology. 2026;33(2):22-31. doi:10.35336/va-1655
BibTeX
@article{Shchukina2026,
author = {Shchukina, Yu. G. and Gasimova, N. Z. and Kobzar, L. Yu. and Gordeeva, M. S. and Harlap, M. S. and Serdyuk, S. E. and Tarasov, A. V. and Davtyan, K. V. and Livadny, E. S. and Mamchur, S. E. and Lebedev, D. S. and Mikhaylov, E. N. and Leandro, H. I. Condori},
title = {Combined antiarrhythmic therapy for refractory paroxysmal atrial fibrillation: a multicenter observational study},
journal = {Journal of Arrhythmology},
year = {2026},
volume = {33},
number = {2},
pages = {22--31},
doi = {10.35336/va-1655}
}
EUVIMED